Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna, Inc. (NASDAQ:MRNA) has announced its acquisition of OriCiro Genomics K.K. for $85 million. This strategic move aims to enhance Moderna's capabilities in mRNA therapeutics by integrating OriCiro's advanced cell-free DNA synthesis technologies. CEO Stéphane Bancel highlighted that the acquisition will significantly bolster their manufacturing processes and R&D efforts. OriCiro's leadership expressed confidence in the synergy between both companies, which is expected to accelerate the development of innovative therapeutics. The acquisition is viewed as a pivotal step in expanding Moderna's technological portfolio.
Moderna, Inc. (NASDAQ:MRNA) will have CEO Stéphane Bancel present its mRNA pipeline updates at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, at 5:15 p.m. ET. Attendees can watch the live webcast on Moderna's investors website, where a recording will also be available for 30 days post-event. Founded a decade ago, Moderna has shifted from a research-focused entity to a leading biotechnology firm with a diverse portfolio in therapeutics and vaccines, including significant contributions to COVID-19 vaccine development.
Moderna has finalized a strategic partnership with the UK government to establish a cutting-edge mRNA research, development, and manufacturing facility, enhancing UK capabilities for pandemic response. This ten-year collaboration aims to make domestically manufactured mRNA respiratory vaccines available, contingent upon regulatory approval. Construction of the Moderna Innovation and Technology Centre is expected to begin in early 2023, with operations starting by 2025. The facility will support the UK's 100 Days Mission to better manage future pandemics.
Moderna, Inc (NASDAQ:MRNA) announced the appointment of Chantal Friebertshäuser as Senior Vice President, Commercial for Europe, the Middle East, and Canada, effective January 1, 2023. With over 15 years of experience from Merck Sharp & Dohme, where she held various leadership roles, Friebertshäuser is expected to enhance Moderna's commercial efforts in these regions. She brings a strong background in global market access and commercial strategy, aligning with Moderna's mission to expand its mRNA platform across diverse therapeutic areas.
Moderna, Inc. (Nasdaq: MRNA) received a positive opinion from the European Medicines Agency's CHMP for the booster dose of its bivalent Omicron-targeting COVID-19 vaccine, mRNA-1273.214, for children aged 6-11. The recommended pediatric dose is 12.5 mcg for both components, administered at least three months after the last vaccine dose. Clinical trials indicate that this booster elicits a stronger antibody response against the Omicron variant compared to previous vaccines. A Phase 2/3 trial for younger children is ongoing, with initial results expected in early 2023.
Moderna and Merck announced positive results from the Phase 2b KEYNOTE-942 trial of mRNA-4157/V940 combined with KEYTRUDA in stage III/IV melanoma patients. The study showed a 44% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone. This marks the first efficacy demonstration of an mRNA cancer treatment in a randomized trial. The companies plan to initiate a Phase 3 study and expand to other tumor types in 2023. Adverse events associated with mRNA-4157/V940 were consistent with previous studies, indicating manageable safety.
Moderna's mRNA-1273.222 has received Emergency Use Authorization (EUA) from the FDA for use in children aged 6 months to 5 years. This bivalent COVID-19 booster vaccine targets the BA.4/BA.5 Omicron variants and is based on clinical trial data showing stronger antibody responses compared to the original vaccine. The EUA extends to pediatric use and has been supported by data from earlier trials. Moderna is also conducting ongoing trials for broader age groups, with results expected in early 2023.
Moderna, Inc. (NASDAQ:MRNA) announces Brad Miller as the new Chief Information Officer effective January 3, taking over from retiring Chief Digital Officer Marcello Damiani in March. Miller brings extensive experience from Capital One, Mastercard, Citibank, Amazon, and Microsoft. His expertise in digital solutions is expected to support Moderna’s growth in mRNA therapeutics and vaccines. Moderna has transitioned over 10 years from a research-stage company to a leading biopharmaceutical entity, recognized for its COVID-19 vaccine and diverse clinical portfolio.
Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 9:00 a.m. ET. A live webcast can be accessed in the 'Events and Presentations' section of its investors website, with a replay available for 30 days post-event. Over the past decade, Moderna has evolved from a research company to a leader in mRNA therapeutics and vaccines, significantly contributing to COVID-19 solutions. For more information, visit modernatx.com.
Moderna (NASDAQ: MRNA) has appointed David Jiménez as General Manager for the United States, effective November 21, 2022. Jiménez brings over two decades of experience from Johnson & Johnson, where he led significant pharmaceutical franchises, including a $10+ billion U.S. Immunology franchise. His expertise is expected to be crucial as Moderna transitions to a commercial vaccine market in the U.S. and develops new candidates in 2023. Moderna's approach to messenger RNA technology continues to impact the COVID-19 pandemic significantly.